Treatment with Relyvrio (sodium phenylbutyrate and taurursodiol) significantly reduced blood levels of neuroinflammatory biomarkers in people with amyotrophic lateral sclerosis (ALS) as early as three months, according to a post hoc analysis of the CENTAUR trial. Data from the Phase 2 study (NCT03127514) demonstrated that reductions in…
Use of ATH-1105, a small molecule being developed by Athira Pharma to treat amyotrophic lateral sclerosis (ALS), protected against nerve damage and improved motor function in a mouse model of the disease, according to data shared in a recent company presentation. Athira is planning to file an…
Eledon Pharmaceuticals’ investigational antibody-based therapy, tegoprubart, safely and effectively reduces levels of inflammatory biomarkers in adults with amyotrophic lateral sclerosis (ALS), according to top-line data from a Phase 2a clinical trial. Exploratory findings suggested that lower levels of inflammatory biomarkers and whether tegoprubart’s target is significantly reduced,…
An analysis of inflammatory marker levels in blood samples from amyotrophic lateral sclerosis (ALS) patients, improves patient categoration and may help design future ALS clinical trials, according to a new study. The study “Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis,” was published in the journal…
